• 1
    ICH. Guidance for industry E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Available at (last accessed 1 August 2012).
  • 2
    Scherer D, Hassel D, Bloehs R, Zitron E, von Löwenstern K, Seyler C, Thomas D, Konrad F, Bürgers HF, Seemann G, Rottbauer W, Katus HA, Karle CA, Scholz EP. Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. Br J Pharmacol 2009; 156: 226236.
  • 3
    Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: cisapride versus dofetilide. J Pharmacol Toxicol Methods 2010; 61: 178191.
  • 4
    Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 2005; 44: 571590.
  • 5
    Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 2004; 64: 205222.
  • 6
    Webster R, Leishman D, Walker D. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Devel 2002; 5: 116126.
  • 7
    Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58: 3245.
  • 8
    Terrar DA, Wilson CM, Graham SG, Bryant SM, Heath BM. Comparison of guinea-pig ventricular myocytes and dog Purkinje fibers for in vitro assessment of drug-induced delayed repolarization. J Pharmacol Toxicol Methods 2007; 56: 171185.
  • 9
    Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26: 729740.
  • 10
    Sawant S, Daviss SR. Seizures and prolonged QTc with atomoxetine overdose. Am J Psychiatry 2004; 161: 757.
  • 11
    Barker MJ, Benitez JG, Ternullo S, Juhl GA. Acute oxcarbazepine and atomoxetine overdose with quetiapine. Vet Hum Toxicol 2004; 46: 130132.
  • 12
    Kashani J, Ruha AM. Isolated atomoxetine overdose resulting in seizure. J Emerg Med 2007; 32: 175178.
  • 13
    Williams EJ. Experimental designs balanced for the estimation of residual effects of treatments. Aust J Sci Res 1949; 2: 149168.
  • 14
    Beasley CM, Mitchell MI, Dmitrienko AA, Emmick JT, Shen W, Costigan TM, Bedding AW, Turik MA, Bakhtyari A, Warner MR, Ruskin JN, Cantilena LR Jr, Kloner RA. The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. J Am Coll Cardiol 2005; 46: 678687.
  • 15
    Couderc JP, Xiaojuan X, Zareba W, Moss AJ. Assessment of the stability of the individual-based correction of QT interval for heart rate. Ann Noninvasive Electrocardio 2005; 10: 2534.
  • 16
    Dmitrienko A, Smith B. Repeated-measures models in the analysis of QT interval. Pharmaceut Statist 2003; 2: 175190.
  • 17
    Fridericia LS. Die Sytolendauer in Elektrokardiogramm bei normalen Menshen und bei Herzkranken. Acta Med Scand 1920; 53: 469486.
  • 18
    Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 2001; 12: 411420.
  • 19
    Salvi V, Karnad DR, Panicker GK, Kothari S. Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. Br J Pharmacol 2010; 159: 3448.
  • 20
    Mullen JH, Shugert RL, Ponsler GD, Li Q, Sundaram B, Coales HL, Yakupkovic JE, Lelacheur RM, Wheeler WJ, Belas FJ, Sauer JM. Simultaneous quantification of atomoxetine as well as its primary oxidative and O-glucuronide metabolites in human plasma and urine using liquid chromatography tandem mass spectrometry (LC/MS/MS). J Pharm Biomed Anal 2005; 38: 720733.
  • 21
    Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, Tornøe CW, Wang Y, Zhu H, Gobburu JV. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 2008; 48: 1318.
  • 22
    Zhang J. Testing for positive control activity in a thorough QTc study. J Biopharm Stat 2008; 18: 517528.
  • 23
    Westfall PH, Young SS. Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment. New York: Wiley, 1993.
  • 24
    Tornøe CW, Garnett CE, Wang Y, Florian J, Li M, Gobburu JV. Creation of a knowledgement management system for QT analyses. J Clin Pharmacol 2011; 51: 10351042.
  • 25
    Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, Gottesdiener K, Wagner JA. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 2008; 84: 475480.
  • 26
    Florian JA, Tornøe CW, Brundage R, Parekh A, Garnett CE. Population pharmacokinetic and concentration-QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J Clin Pharmacol 2011; 51: 11521162.
  • 27
    Burke JH, Ehlert FA, Kruse JT, Parker MA, Goldberger JJ, Kadish AH. Gender-specific differences in the QT interval and the effect of autonomic tone and menstrual cycle in healthy adults. Am J Cardiol 1997; 79: 178181.
  • 28
    Rodriguez I, Kilborn MJ, Liu X-K, Pezzullo JC, Woosley RL. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001; 285: 13221326.
  • 29
    Nakagawa M, Ooie T, Takahashi N, Taniguchi Y, Anan F, Yonemochi H, Saikawa T. Influence of menstrual cycle on QT interval dynamics. Pacing Clin Electrophysiol 2006; 29: 607613.
  • 30
    Somberg JC, Preston RA, Ranade V, Cvetanovic I, Molnar J. Gender differences in cardiac repolarization following intravenous sotalol administration. J Cardiovasc Pharmacol Ther 2012; 17: 8692.